Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Improved therapeutic method for rare ocular diseases by gene replacement

a gene replacement and rare ocular disease technology, applied in the direction of genetic material ingredients, peptide sources, peptide sources, etc., can solve the problems of limited number of therapeutic approaches initiated for these dominant forms, and the dominant forms of pr degeneration are more difficult to cur

Pending Publication Date: 2022-06-09
UNIV PARIS SACLAY +3
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a new method for treating a specific type of retinal disease by using a therapeutic compound delivered into the eye. This method has shown promising results in reducing symptoms and improving quality of life for patients with the disease. Overall, this invention offers a novel way to potentially treat a previously incurable retinal disease.

Problems solved by technology

Nowadays, very limited number of therapeutic approaches have been initiated for these dominant forms.
Therefore, in contrast with recessive forms, dominant forms of PR degeneration are more challenging to cure since restoring a missing function may not be sufficient.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Improved therapeutic method for rare ocular diseases by gene replacement
  • Improved therapeutic method for rare ocular diseases by gene replacement
  • Improved therapeutic method for rare ocular diseases by gene replacement

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0114]Material and Methods Animals

[0115]Male and female adult (3-8 weeks old) C57BL / 6J, CrxRip / + and Tg(CRXR41W) mices, and male and female young (2 weeks old) rd10 mices were produced in the laboratory animal facilities (Animalerie central-campus CNRS Gif sur Yvette).

[0116]All animal experiments were carried out according to European guidelines for the care and use of experimental animals, and were approved by the regional ethics committee (CEEA59).

Vectors

[0117]rAAV2 / 5 vectors expressing green fluorescent protein (GFP) or human cone-rod homeobox protein (CRX) under the control of the human rhodopsin kinase (GRK1) promotor were produced.

1. Vector Plasmid Cloning (822-pKL.AAV.GRK1.hCRX Vector #6556 Batch)

[0118]The vector plasmid was constructed in 2 phases as described below:[0119]First, the promoter GRK1 was extracted from the 754-pAAV.GRK1.eGFP.wpre.bGH by double digestion SpeI (position 185) and EcoR1 (position 427) and inserted in the 778-pKL.AAV.CAG.bGH vector plasmid in advance...

example 2

[0148]Selection of the promoter and the serotypes of the AAV vector to be used to efficiently transduced photoreceptors in CRX-associated retinopathy mouse models.

[0149]Several AAV serotypes and promoters have been tested and showed transduction of mature photoreceptors in adults. In the case of CrxRip / + retina, the outer nuclear layer contains only immature cone-like photoreceptors and therefore AAV vectors commonly used to treat differentiated photoreceptors may not be as efficient. Therefore, we tested several serotypes expressing GFP driven by a photoreceptor-specific promoter, which directs gene expression in both rod and cone photoreceptors. The human Rhodopsin kinase 1 (GRK1) promoter was selected because i) it is already well characterized to express genes in both rod and cone photoreceptors ii) it is already used in clinical trial (PDE6B) iii) It is active in our mouse models based on our published transcriptomic data. For the serotype, we selected the AAV2 / 5 vector describ...

example 3

[0152]Quantification of CRX expression driven by GRK1 promoter using an AAV2 / 5 vector.

[0153]In order to verify that the product (CRX-expressing AAV vector or AAV-CRX) is able to produce CRX protein, a series of subretinal injections was performed in CrxRip / + retina with three different doses (0.5·1010, 1·1010 and 2.5·1010 vg) and CRX expression was assessed 14 days later. At all three tested doses, increased expression of CRX was observed. The amount produced was more dependent of the injection than the dose used (FIG. 3). This experiment was repeated when the subretinal injection technic was fully mastered but this time GFP-expressing vector (AAV-GFP) was injected as control (FIG. 4) at three different doses (0.5·1010, 1·1010 and 2.5·1010 vg). CRX relative expression was quantified after tubulin normalization and reported to endogenous CRX expression following AAV-GFP injection at 0.5·1010 vg. CRX expression was clearly significantly increased after AAV-CRX injection proportionally...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

A recombinant adeno-associated virus (AAV) vector that carries a nucleic acid sequence encoding the retinal transcription factor cone-rod homeobox (CRX) for its use in treating CRX-associated IRDs in a subject in need thereof or for use in treating inherited retinal dystrophies caused by hypomorphic mutations in the CRX target genes.

Description

FIELD OF INVENTION[0001]The present invention relates to methods for treating retinal diseases and pharmaceutical compositions comprising CRX as an active agent.BACKGROUND OF INVENTION[0002]Progressive loss of photoreceptors (PR) in inherited retinal diseases (IRDs) are common causes of visual impairment with a prevalence of 1 / 4,000, representing about 17,000 patients in France. They form a group of genetically and clinically heterogeneous diseases with more than sixty human genes identified. The efficacy and safety of gene therapies, by the mean of intraocular injections of Adeno-Associated Virus (AAV), have been proven with preclinical success translated into clinical effectiveness. Such approaches are mostly used in patients with recessive loss of function mutations. The goal is to compensate the mutated gene that causes the disease with a fully functional copy.[0003]Dominant forms of PR degeneration represent at least 20% of retinitis pigmentosa (RP) cases. Nowadays, very limite...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K48/00C07K14/47C12N15/86
CPCA61K48/005C07K2319/41C12N15/86C07K14/4705A61K48/0058A01K2217/075A01K2227/105A01K2267/0306
Inventor ROGER, JÉRÔMEGRELLIER, ELODIE KIM
Owner UNIV PARIS SACLAY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com